Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005 brain cancer drug. Shares -12.2% AH to $1.30.